A5049985208- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Liver Diseases and Immunity
- Organ Transplantation Techniques and Outcomes
- Alcohol Consumption and Health Effects
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Renal Transplantation Outcomes and Treatments
- Diet, Metabolism, and Disease
- Organ Donation and Transplantation
- Pharmaceutical Economics and Policy
- Substance Abuse Treatment and Outcomes
- Psoriasis: Treatment and Pathogenesis
- Advanced MRI Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pharmaceutical industry and healthcare
- Reproductive Health and Contraception
- Circadian rhythm and melatonin
- Health and Medical Research Impacts
- Neuroblastoma Research and Treatments
- Ectopic Pregnancy Diagnosis and Management
- Viral-associated cancers and disorders
- Dietary Effects on Health
University of California, San Diego
2019-2025
Association of Organ Procurement Organizations
2023
St Bartholomew's Hospital
2016
University of Pittsburgh
2014
ABSTRACT Background There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse injury. Guselkumab, an IL‐23‐specific antibody approved psoriasis, be beneficial ALD. Aims We aimed to assess the safety and tolerability of guselkumab in patients with Methods This phase‐1 dose‐escalation study included ≥ 2 DSM‐5 criteria alcohol use disorder, significant steatosis (MRI‐PDFF 8%) MRE < 3.63 kPa...
BACKGROUNDA pilot, single-center study showed that first-degree relatives of probands with nonalcoholic fatty liver disease (NAFLD) cirrhosis have a high risk advanced fibrosis. We aimed to validate these findings using 2 independent cohorts from the US and Europe.METHODSThis prospective included NAFLD fibrosis, without non-NAFLD, at least 1 relative. A total 396 - 220 in derivation cohort 176 validation were enrolled study, fibrosis was evaluated magnetic resonance elastography other...
Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS ("All-comers" (AC)) been limited by small sample size and short follow-up time, prompting this analysis. 326 patients 190 AC from 9 LT centers across 5 UNOS regions were enrolled 2015 to 2023 prospectively followed. Competing risk analysis Kaplan-Meier method used evaluate downstaging outcomes, Fine-and-Gray Cox models...
Background: The RETREAT score is a simple risk stratification tool for post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study needed to further demonstrate accuracy especially given evolving clinical demographics and HCC transplant practice. Aim: To validate compare the other post-LT scores contemporary, prospective of patients Approach: We prospectively enrolled from 8 centers...
Financial relationships between the pharmaceutical industry and physicians have come under increased scrutiny. Less attention has been paid to leadership of academic medical centers (AMCs), who wield considerable influence over research, clinical, educational missions. When AMC leaders serve on company boards, they hold a fiduciary responsibility shareholders promote financial success company, which may conflict or compete with institutional oversight responsibilities individual clinical...
Abstract Medical management of the liver transplant recipient requires consideration complex interactions between transplanted liver, immunosuppression and all organ systems. An aging population, improvement in long-term outcomes, increase nonalcoholic fatty disease as an indication for have amplified number co-morbidities among post-transplant patients. In addition to balancing with infection risk, medical patient includes monitoring for, treating, recurrence primary disease, metabolic...